{"id":"NCT00537238","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Pregabalin Versus Levetiracetam In Partial Seizures","officialTitle":"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2007-10-01","resultsPosted":"2013-07-11","lastUpdate":"2021-01-28"},"enrollment":509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"levetiracetam","otherNames":[]}],"arms":[{"label":"B","type":"ACTIVE_COMPARATOR"},{"label":"A","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.","primaryOutcome":{"measure":"Proportion of Participants With Response to Treatment","timeFrame":"Baseline up to Week 16","effectByArm":[{"arm":"Pregabalin","deltaMin":0.59,"sd":null},{"arm":"Levetiracetam","deltaMin":0.59,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":72,"countries":["Belgium","Bulgaria","Colombia","Costa Rica","Czechia","France","Germany","Greece","India","Italy","Lithuania","Mexico","Panama","Peru","Philippines","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Venezuela"]},"refs":{"pmids":["24902473"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":254},"commonTop":["Somnolence","Dizziness","Headache","Nasopharyngitis","Weight increased"]}}